THOC5 was significantly upregulated in cancers such as glioblastoma multiforme (GBM), lower-grade glioma (LGG), kidney renal papillary cell carcinoma (KIRP), stomach adenocarcinoma (STAD), and liver hepatocellular carcinoma (LIHC), among others, while being downregulated in cancers including breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), prostate adenocarcinoma (PRAD), and adrenocortical carcinoma (ACC). Here, THOC5 is linked to prostate adenocarcinoma.